| $337M | ||
| $259M | ||
| $100M | ||
| $79M | ||
| $60M | ||
| $58M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Over the last 12 months, insiders at XTL Biopharmaceuticals Ltd. have bought $0 and sold $0 worth of XTL Biopharmaceuticals Ltd. stock.
On average, over the past 5 years, insiders at XTL Biopharmaceuticals Ltd. have bought $0 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 51,000 shares for transaction amount of $164,730 was made by EDELMAN JOSEPH (10 percent owner) on 2008‑06‑10.
| 2008-11-19 | Sale | EDELMAN JOSEPH | 10 percent owner | 9.6M 6.44% | $0.15 | $1.47M | +40.00% | |
| 2008-11-18 | Sale | EDELMAN JOSEPH | 10 percent owner | 30.45M 19.0502% | $0.14 | $4.34M | +7.69% | |
| 2008-06-10 | EDELMAN JOSEPH | 10 percent owner | 51,000 0.7232% | $3.23 | $164,730 | -92.26% | ||
| 2008-06-09 | EDELMAN JOSEPH | 10 percent owner | 33,600 0.4956% | $3.36 | $112,896 | -92.63% | ||
| 2008-06-06 | EDELMAN JOSEPH | 10 percent owner | 100,000 1.5059% | $3.43 | $343,000 | -92.84% | ||
| 2008-06-05 | EDELMAN JOSEPH | 10 percent owner | 300,000 4.2453% | $3.22 | $967,000 | -92.75% | ||
| 2008-06-04 | EDELMAN JOSEPH | 10 percent owner | 25,000 0.3282% | $2.99 | $74,750 | -91.61% | ||
| 2008-06-03 | EDELMAN JOSEPH | 10 percent owner | 400,730 5.3307% | $3.03 | $1.21M | -91.75% | ||
| 2008-05-02 | EDELMAN JOSEPH | 10 percent owner | 50,000 0.8517% | $3.88 | $194,000 | -40.41% | ||
| 2008-05-01 | EDELMAN JOSEPH | 10 percent owner | 105,000 1.7287% | $3.75 | $393,750 | -40.21% | ||
| 2008-04-30 | EDELMAN JOSEPH | 10 percent owner | 128,370 2.1099% | $3.74 | $480,579 | -38.42% | ||
| 2008-04-29 | EDELMAN JOSEPH | 10 percent owner | 229,240 3.5606% | $3.54 | $811,028 | -37.30% | ||
| 2008-04-10 | EDELMAN JOSEPH | 10 percent owner | 100,000 1.5699% | $3.58 | $357,590 | -21.02% | ||
| 2008-04-01 | EDELMAN JOSEPH | 10 percent owner | 301,000 4.1792% | $3.16 | $951,913 | -2.87% | ||
| 2008-03-28 | EDELMAN JOSEPH | 10 percent owner | 25,000 0.3181% | $2.90 | $72,460 | +2.34% | ||
| 2008-03-18 | EDELMAN JOSEPH | 10 percent owner | 163,000 2.2329% | $3.12 | $508,593 | -1.89% | ||
| 2008-03-14 | EDELMAN JOSEPH | 10 percent owner | 463,000 6.7626% | $3.33 | $1.54M | -6.55% | ||
| 2008-03-13 | EDELMAN JOSEPH | 10 percent owner | 247,000 3.6626% | $3.38 | $834,234 | -9.25% | ||
| 2008-03-12 | EDELMAN JOSEPH | 10 percent owner | 440,000 6.4821% | $3.36 | $1.48M | -6.40% | ||
| 2008-03-11 | EDELMAN JOSEPH | 10 percent owner | 619,000 8.9963% | $3.31 | $2.05M | -5.69% |
| EDELMAN JOSEPH | 10 percent owner | 20580260 233.4991% | $36.22M | 61 | 2 | |
| BENTSUR RON | CEO | 20101 0.2281% | $35,377.76 | 2 | 0 | +144.27% |
$1,848,072 | 66 | -14.67% | $11.78M | |
$1,018,029 | 34 | -26.34% | $11.51M | |
$95,303,339 | 30 | -13.78% | $13.92M | |
$523,320 | 24 | 94.37% | $11.57M | |
$226,127 | 22 | -27.62% | $16.85M | |
$555,628 | 21 | 43.52% | $16.67M | |
$114,405,653 | 19 | -5.40% | $15.93M | |
$53,355 | 19 | -41.05% | $11.76M | |
$112,810,270 | 18 | -1.20% | $19.24M | |
$39,336,371 | 14 | -17.87% | $17.89M | |
$1,199,157 | 14 | 7.52% | $19.15M | |
$941,975 | 12 | -10.74% | $11.55M | |
$36,538,405 | 10 | -21.99% | $13.91M | |
$11,777,042 | 10 | -11.94% | $17.1M | |
$70,584,874 | 10 | 3.97% | $14.26M | |
$2,889,596 | 6 | -43.43% | $14.58M | |
$2,060,158 | 5 | -21.35% | $16.69M | |
$82,917 | 4 | -11.54% | $18.42M | |
XTL Biopharmaceuticals Ltd. (XTLB) | $19,863 | 1 | 144.27% | $15.51M |
| Increased Positions | <1 | +25% | 25,211 | +11.05% |
| Decreased Positions | <1 | -25% | 5,100 | -2.23% |
| New Positions | <1 | New | 25,211 | New |
| Sold Out Positions | 0 | Sold Out | 0 | Sold Out |
| Total Postitions | 4 | 0% | 248,304 | +8.81% |
| Noked Israel Ltd | $298.00 | 1.53% | 198,888 | 0 | 0% | 2024-12-31 |
| Morgan Stanley | $28.00 | 0.14% | 18,351 | -8,100 | -30.62% | 2024-12-31 |
| Rhumbline Advisers | $16.00 | 0.08% | 10,954 | 0 | 0% | 2025-03-31 |